Merck & Co. Inc. has announced plans to initiate clinical development of a new investigational multi-valent human papillomavirus (HPV) vaccine designed to provide broader protection against multiple HPV types.
The phase II Initium study of Ultimovacs ASA’s therapeutic cancer vaccine in treating unresectable or metastatic malignant melanoma did not meet the primary endpoint. The company framed the loss by saying the UV-1 vaccine still has other indications where it could succeed.